PLSE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pulse Biosciences Inc (PLSE) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown some early commercial traction and received FDA approvals for clinical trials, its financials indicate significant losses, declining cash reserves, and insider selling. Additionally, technical indicators suggest a bearish trend, and there are no strong trading signals or recent influential purchases to support a buy decision.
The MACD histogram is negative (-0.54) and expanding, indicating bearish momentum. RSI is neutral at 37.137, and moving averages are converging, showing no clear directional trend. The stock is trading near its support level (S1: 19.309), with resistance levels at R1: 24.879 and R2: 26.599.
FDA approval for pivotal IDE study of nPulse Cardiac Catheter.
Early commercial traction with a 207% revenue increase QoQ in Q4
Expanded patent portfolio with 250 granted and 180 pending patents.
Significant insider selling, with a 3340.02% increase in the last month.
Declining cash reserves, down 32% YoY to $80.7 million.
Announced $200 million shelf registration and $60 million stock sale, raising concerns over dilution and liquidity.
Bearish technical indicators and lack of strong trading signals.
In Q4 2025, revenue increased to $264,000, up 207% QoQ but flat YoY. Net income dropped to -$17.43 million (-10.07% YoY), and EPS fell to -$0.26 (-16.13% YoY). Gross margin improved slightly to 1.52.
Analysts are bullish, with Oppenheimer and Mizuho raising price targets to $30 and maintaining Outperform ratings. Positive sentiment is driven by FDA approvals and early commercial traction, but analysts note the need for confirmation of feasibility study results in larger trials.
